Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.

Claudio Tripodo, Carmelo Carlo-Stella, Roberta Zappasodi, Massimo Di Nicola, Alessandro M. Gianni, Gaia C. Ghedini, Lorenzo Castagnoli, Antonello D. Cabras, Monica Tortoreto, Serenella M. Pupa, Italia Bongarzone, Michele Magni, Antonella Messina

Risultato della ricerca: Article

19 Citazioni (Scopus)

Abstract

We reported that the clinical efficacy of dendritic cell-based vaccination is strongly associated with immunologic responses in relapsed B-cell non-Hodgkin lymphoma (B-NHL) patients. We have now investigated whether postvaccination antibodies from responders recognize novel shared NHL-restricted antigens. Immunohistochemistry and flow cytometry showed that they cross-react with allogeneic B-NHLs at significantly higher levels than their matched prevaccination samples or nonresponders' antibodies. Western blot analysis of DOHH-2 lymphoma proteome revealed a sharp band migrating at approximately 100 to 110 kDa only with postvaccine repertoires from responders. Mass spectrometry identified heat shock protein-105 (HSP105) in that molecular weight interval. Flow cytometry and immunohistochemistry disclosed HSP105 on the cell membrane and in the cytoplasm of B-NHL cell lines and 97 diagnostic specimens. A direct correlation between HSP105 expression and lymphoma aggressiveness was also apparent. Treatment of aggressive human B-NHL cell lines with an anti-HSP105 antibody had no direct effects on cell cycle or apoptosis but significantly reduced the tumor burden in xenotransplanted immunodeficient mice. In vivo antilymphoma activity of HSP105 engagement was associated with a significant local increase of Granzyme B(+) killer cells that very likely contributed to the tumor-restricted necrosis. Our study adds HSP105 to the list of nononcogenes that can be exploited as antilymphoma targets.
Lingua originaleEnglish
pagine (da-a)4421-4430
Numero di pagine10
RivistaBlood
Volume118
Stato di pubblicazionePublished - 2011

Fingerprint

Heat-Shock Proteins
Non-Hodgkin's Lymphoma
Cells
B-Cell Lymphoma
Flow cytometry
Antibodies
Tumors
Lymphoma
Flow Cytometry
Therapeutics
Immunohistochemistry
Granzymes
Cell Line
Proteome
Cell membranes
Tumor Burden
Dendritic Cells
Mass spectrometry
Mass Spectrometry
Cell Cycle

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cita questo

Tripodo, C., Carlo-Stella, C., Zappasodi, R., Di Nicola, M., Gianni, A. M., Ghedini, G. C., ... Messina, A. (2011). Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood, 118, 4421-4430.

Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. / Tripodo, Claudio; Carlo-Stella, Carmelo; Zappasodi, Roberta; Di Nicola, Massimo; Gianni, Alessandro M.; Ghedini, Gaia C.; Castagnoli, Lorenzo; Cabras, Antonello D.; Tortoreto, Monica; Pupa, Serenella M.; Bongarzone, Italia; Magni, Michele; Messina, Antonella.

In: Blood, Vol. 118, 2011, pag. 4421-4430.

Risultato della ricerca: Article

Tripodo, C, Carlo-Stella, C, Zappasodi, R, Di Nicola, M, Gianni, AM, Ghedini, GC, Castagnoli, L, Cabras, AD, Tortoreto, M, Pupa, SM, Bongarzone, I, Magni, M & Messina, A 2011, 'Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.', Blood, vol. 118, pagg. 4421-4430.
Tripodo C, Carlo-Stella C, Zappasodi R, Di Nicola M, Gianni AM, Ghedini GC e altri. Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood. 2011;118:4421-4430.
Tripodo, Claudio ; Carlo-Stella, Carmelo ; Zappasodi, Roberta ; Di Nicola, Massimo ; Gianni, Alessandro M. ; Ghedini, Gaia C. ; Castagnoli, Lorenzo ; Cabras, Antonello D. ; Tortoreto, Monica ; Pupa, Serenella M. ; Bongarzone, Italia ; Magni, Michele ; Messina, Antonella. / Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. In: Blood. 2011 ; Vol. 118. pagg. 4421-4430.
@article{3e117ee1856944bdaf60bee20fb5e3c5,
title = "Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.",
abstract = "We reported that the clinical efficacy of dendritic cell-based vaccination is strongly associated with immunologic responses in relapsed B-cell non-Hodgkin lymphoma (B-NHL) patients. We have now investigated whether postvaccination antibodies from responders recognize novel shared NHL-restricted antigens. Immunohistochemistry and flow cytometry showed that they cross-react with allogeneic B-NHLs at significantly higher levels than their matched prevaccination samples or nonresponders' antibodies. Western blot analysis of DOHH-2 lymphoma proteome revealed a sharp band migrating at approximately 100 to 110 kDa only with postvaccine repertoires from responders. Mass spectrometry identified heat shock protein-105 (HSP105) in that molecular weight interval. Flow cytometry and immunohistochemistry disclosed HSP105 on the cell membrane and in the cytoplasm of B-NHL cell lines and 97 diagnostic specimens. A direct correlation between HSP105 expression and lymphoma aggressiveness was also apparent. Treatment of aggressive human B-NHL cell lines with an anti-HSP105 antibody had no direct effects on cell cycle or apoptosis but significantly reduced the tumor burden in xenotransplanted immunodeficient mice. In vivo antilymphoma activity of HSP105 engagement was associated with a significant local increase of Granzyme B(+) killer cells that very likely contributed to the tumor-restricted necrosis. Our study adds HSP105 to the list of nononcogenes that can be exploited as antilymphoma targets.",
author = "Claudio Tripodo and Carmelo Carlo-Stella and Roberta Zappasodi and {Di Nicola}, Massimo and Gianni, {Alessandro M.} and Ghedini, {Gaia C.} and Lorenzo Castagnoli and Cabras, {Antonello D.} and Monica Tortoreto and Pupa, {Serenella M.} and Italia Bongarzone and Michele Magni and Antonella Messina",
year = "2011",
language = "English",
volume = "118",
pages = "4421--4430",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.

AU - Tripodo, Claudio

AU - Carlo-Stella, Carmelo

AU - Zappasodi, Roberta

AU - Di Nicola, Massimo

AU - Gianni, Alessandro M.

AU - Ghedini, Gaia C.

AU - Castagnoli, Lorenzo

AU - Cabras, Antonello D.

AU - Tortoreto, Monica

AU - Pupa, Serenella M.

AU - Bongarzone, Italia

AU - Magni, Michele

AU - Messina, Antonella

PY - 2011

Y1 - 2011

N2 - We reported that the clinical efficacy of dendritic cell-based vaccination is strongly associated with immunologic responses in relapsed B-cell non-Hodgkin lymphoma (B-NHL) patients. We have now investigated whether postvaccination antibodies from responders recognize novel shared NHL-restricted antigens. Immunohistochemistry and flow cytometry showed that they cross-react with allogeneic B-NHLs at significantly higher levels than their matched prevaccination samples or nonresponders' antibodies. Western blot analysis of DOHH-2 lymphoma proteome revealed a sharp band migrating at approximately 100 to 110 kDa only with postvaccine repertoires from responders. Mass spectrometry identified heat shock protein-105 (HSP105) in that molecular weight interval. Flow cytometry and immunohistochemistry disclosed HSP105 on the cell membrane and in the cytoplasm of B-NHL cell lines and 97 diagnostic specimens. A direct correlation between HSP105 expression and lymphoma aggressiveness was also apparent. Treatment of aggressive human B-NHL cell lines with an anti-HSP105 antibody had no direct effects on cell cycle or apoptosis but significantly reduced the tumor burden in xenotransplanted immunodeficient mice. In vivo antilymphoma activity of HSP105 engagement was associated with a significant local increase of Granzyme B(+) killer cells that very likely contributed to the tumor-restricted necrosis. Our study adds HSP105 to the list of nononcogenes that can be exploited as antilymphoma targets.

AB - We reported that the clinical efficacy of dendritic cell-based vaccination is strongly associated with immunologic responses in relapsed B-cell non-Hodgkin lymphoma (B-NHL) patients. We have now investigated whether postvaccination antibodies from responders recognize novel shared NHL-restricted antigens. Immunohistochemistry and flow cytometry showed that they cross-react with allogeneic B-NHLs at significantly higher levels than their matched prevaccination samples or nonresponders' antibodies. Western blot analysis of DOHH-2 lymphoma proteome revealed a sharp band migrating at approximately 100 to 110 kDa only with postvaccine repertoires from responders. Mass spectrometry identified heat shock protein-105 (HSP105) in that molecular weight interval. Flow cytometry and immunohistochemistry disclosed HSP105 on the cell membrane and in the cytoplasm of B-NHL cell lines and 97 diagnostic specimens. A direct correlation between HSP105 expression and lymphoma aggressiveness was also apparent. Treatment of aggressive human B-NHL cell lines with an anti-HSP105 antibody had no direct effects on cell cycle or apoptosis but significantly reduced the tumor burden in xenotransplanted immunodeficient mice. In vivo antilymphoma activity of HSP105 engagement was associated with a significant local increase of Granzyme B(+) killer cells that very likely contributed to the tumor-restricted necrosis. Our study adds HSP105 to the list of nononcogenes that can be exploited as antilymphoma targets.

UR - http://hdl.handle.net/10447/60713

M3 - Article

VL - 118

SP - 4421

EP - 4430

JO - Blood

JF - Blood

SN - 0006-4971

ER -